The galanin receptor type 1 (GALR1) is a G protein-coupled receptor (GPCR) that binds the neuropeptide galanin, mediating its diverse physiological roles in the central and peripheral nervous systems. GALR1 is widely expressed in brain regions such as the hypothalamus, amygdala, and dorsal root ganglia, influencing processes like pain perception, appetite regulation, mood, and neuroendocrine functions. Its activation typically inhibits neurotransmitter release via Gi/o protein signaling, modulating neuronal excitability. GALR1 antibodies are essential tools for studying receptor localization, expression levels, and functional interactions in tissues or cell models. These antibodies (polyclonal or monoclonal) are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research involving GALR1 antibodies has explored its involvement in neurological disorders (e.g., epilepsy, depression, Alzheimer’s disease) and cancer, where GALR1 downregulation is linked to tumor progression. Additionally, they aid in pharmacological studies targeting galaninergic pathways for therapeutic development. Reliable GALR1 antibodies require specificity testing against related receptors (GALR2. GALR3) to avoid cross-reactivity, ensuring accurate interpretation in experimental models.